Form 4: CytomX Therapeutics Director Matthew P. Young Acquires 38,000 Stock Options
SEC Form 4 Filing
Director Matthew P. Young acquired 38,000 stock options in CytomX Therapeutics, Inc. on May 15, 2024.
Summary
- On May 15, 2024, Matthew P. Young, a director of CytomX Therapeutics, Inc., acquired 38,000 stock options.
- The exercise price of these options is $1.96.
- The options vest and become exercisable on the earlier of May 15, 2025, or the date of the 2025 Annual Meeting of the Issuer's stockholders, assuming continuous service as a director.
- The options expire on May 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing detailing the acquisition of stock options by a company director. While insider ownership can be a positive signal, this specific transaction doesn't inherently indicate strong positive or negative sentiment.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Future Outlook
The document does not contain specific forward-looking statements about the company's future performance beyond the vesting and expiration dates of the options.
Industry Context
This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company directors and their investment in the company's stock.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of transaction: Matthew P. Young acquired 38,000 stock options. |
| 05/15/2025 | Earliest vesting date for the stock options, contingent upon continuous service as a director. |
| 05/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.